Physician profile
Anca Avram
NPI 1174616098
$10,682.89
in general payments reported to CMS, 2019-2025
9 companies · $5,162 in 2025
The $5,162 reported for 2025 was more than what 93% of Nuclear Medicine providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $71.40 · 2023: $221 · 2024: $5,228 · 2025: $5,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,625 · Travel and Lodging: $1,907 · Food and Beverage: $1,037 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,625.00 |
| Travel and Lodging | $1,906.51 |
| Food and Beverage | $1,036.73 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,625.00 | 2024-2025 | |
| Telix Pharmaceuticals | $2,297.77 | 2025 | Illuccix |
| Ge Healthcare | $165.33 | 2024 | |
| Dexcom, INC. | $164.91 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $161.96 | 2025 | |
| Xeris Pharmaceuticals, INC. | $134.08 | 2022-2024 | Gvoke Hypopen |
| Genzyme Corporation | $56.40 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $43.25 | 2025 | Enhertu |
| Tandem Diabetes Care, INC. | $34.19 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anca Avram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.